Tenderwize
Retour à la recherche

Non-exclusive drug discount agreement for Vilanterol/Fluticasone

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Mar 31, 2028 · 581 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Vilanterol/Fluticason (ATC-Code nach WHO: R03AK10)

60/100

Score d'opportunité

PromisingLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

60 / 100

Complexité

15 / 100

Facteurs de risque

No guaranteed minimum purchase; actual revenue is uncertain and may be low.

The Open-House procedure may be terminated early if exclusive agreements are concluded, ending existing discount agreem...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Strong opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Mar 2028
  • Supply of pharmaceutical products containing Vilanterol/Fluticasone (ATC R03AK10) under a non-exclusive discount agreement.
  • The agreement is open to all interested pharmaceutical companies that meet the participation requirements.
Afficher le résumé complet

This is a non-exclusive drug discount agreement (Rabattvereinbarung) under § 130a Abs. 8 SGB V for the active substance Vilanterol/Fluticasone (ATC R03AK10) via an Open-House model. The contracting authority is AOK PLUS, covering Saxony and Thuringia. The procedure is not a classic public procurement but a voluntary transparency publication. No estimated value, no guaranteed purchase quantities, and no exclusivity. The agreement ends 31 March 2028. Submission via DTVP portal; first deadline 5 March 2026.

Risques

No guaranteed minimum purchase; actual revenue is uncertain and may be low.

The Open-House procedure may be terminated early if exclusive agreements are concluded, ending existing discount agreem...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur as defined in § 4 Abs. 18 AMG for the offered medicinal products.

Eligibility

  • Must submit a declaration of no conflict of interest (exclusion grounds per §§ 123, 124 GWB).

Administrative

  • Must submit a declaration regarding Russia sanctions (EU Regulation 833/2014).

Critères d'attribution

Lot 1

No explicit award criteria provided; the agreement is based on acceptance of predetermined discount terms.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Non-exclusive drug discount agreement for Vilanterol/Fluticasone

Open-House model for non-exclusive discount agreements on pharmaceuticals containing Vilanterol/Fluticasone (ATC R03AK10). No exclusivity, no guaranteed minimum purchase. The agreement term ends 31 March 2028. Participation requires acceptance of the discount terms and confidentiality obligations.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Mar 2026 - Mar 2028

Catégorie

Pharmaceutical products

Critères d'attribution

No explicit award criteria provided; the agreement is based on acceptance of predetermined discount terms.

Date limite

Expired Mar 05, 2026

Détails de la procédure

Date de publication
15 Jan 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
32969-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30